Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy

類似資料

• Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
  著者:: Wang, Wei, 等
  出版事項: (2016)
• Advances in treatment of chronic myelogenous leukemia – new treatment options with tyrosine kinase inhibitors
  著者:: SANTOS, FABIO P. S., 等
  出版事項: (2009)
• Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy
  著者:: Pemmaraju, Naveen, 等
  出版事項: (2012)
• NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia
  著者:: O’Brien, Susan, 等
  出版事項: (2011)
• Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
  著者:: Druker, Brian J., 等
  出版事項: (2000)